February 11, 2010 — The US Food and Drug Administration (FDA) has approved once-daily trazodone HCl extended-release tablets (Oleptro, Labopharm, Inc) for the treatment of major depressive disorder in ...

Small Pharma is evaluating the best way to administer N,N-dimethyltryptamine (DMT) in a therapeutic setting for the treatment of depressive disorders. DMT—the primary psychoactive compound in ...

LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant ...

Dosages for the Phase IIa programme were selected following the successful completion of the double-blind stage of Beckley Psytech’s Phase I study earlier this year, which showed that BPL-003 was well ...

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...

Compass Pathways plc is poised to start the first ever phase III trial of the psychedelic drug psilocybin, after getting U.S. FDA backing for a study in treatment-resistant depression. The phase III, ...

In the U.S. women are far more likely than men to seek treatment for depression—as with all other conditions. Nevertheless, it is extremely important for anyone suffering to take steps to treat ...

Treating depression involves multiple costs, including medications and therapy sessions, which can be a financial strain, especially without insurance. Brand-name and generic antidepressant ...

Depression is characterized by a persistent low mood and loss of interest, while anxiety involves overwhelming worry and fear. Both conditions can significantly impair daily life and well-being. While ...